Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high‐risk locally advanced cervical cancer 🔗 Access full article via ACS CancerCancer, Volume 131, Issue 2, 15 January 2025. Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
